CA2332121A1 - Methods for inhibiting tef-3 activity - Google Patents

Methods for inhibiting tef-3 activity Download PDF

Info

Publication number
CA2332121A1
CA2332121A1 CA002332121A CA2332121A CA2332121A1 CA 2332121 A1 CA2332121 A1 CA 2332121A1 CA 002332121 A CA002332121 A CA 002332121A CA 2332121 A CA2332121 A CA 2332121A CA 2332121 A1 CA2332121 A1 CA 2332121A1
Authority
CA
Canada
Prior art keywords
tef
cdna
cells
binding
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002332121A
Other languages
English (en)
French (fr)
Inventor
Michael Howard Tindal
Richard Liqun Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2332121A1 publication Critical patent/CA2332121A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002332121A 1998-06-30 1999-06-30 Methods for inhibiting tef-3 activity Abandoned CA2332121A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9131898P 1998-06-30 1998-06-30
US60/091,318 1998-06-30
PCT/US1999/014829 WO2000000161A2 (en) 1998-06-30 1999-06-30 Methods for identification of tef-3 interacting factors

Publications (1)

Publication Number Publication Date
CA2332121A1 true CA2332121A1 (en) 2000-01-06

Family

ID=22227169

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002332121A Abandoned CA2332121A1 (en) 1998-06-30 1999-06-30 Methods for inhibiting tef-3 activity

Country Status (7)

Country Link
EP (1) EP1089794A2 (xx)
JP (1) JP2002519008A (xx)
AU (1) AU5086699A (xx)
CA (1) CA2332121A1 (xx)
IL (1) IL140058A0 (xx)
NO (1) NO20006198L (xx)
WO (1) WO2000000161A2 (xx)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003001906A1 (fr) * 2001-06-27 2003-01-09 Takeda Chemical Industries, Ltd. Procede de construction d'un modele animal de maladie des articulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824794A (en) * 1994-12-23 1998-10-20 Syntex (U.S.A.) Inc. Human stromelysin-1 promoter
US5569588A (en) * 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
EP0935753A4 (en) * 1996-10-31 1999-12-08 Merck & Co Inc TEST ARRANGEMENT AND CELL LINE FOR IDENTIFYING MIMETICS OF GROWTH HORMONES
US6200760B1 (en) * 1997-02-24 2001-03-13 Cornell Research Foundation, Inc. Method of screening agents as candidates for drugs or sources of drugs

Also Published As

Publication number Publication date
EP1089794A2 (en) 2001-04-11
WO2000000161A3 (en) 2001-01-04
NO20006198L (no) 2001-02-28
NO20006198D0 (no) 2000-12-06
WO2000000161A2 (en) 2000-01-06
AU5086699A (en) 2000-01-17
JP2002519008A (ja) 2002-07-02
IL140058A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
US8187596B1 (en) Method of treating asthma or allergy by administering an IL-33 receptor antibody
US20210189342A1 (en) Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof
JP2002504818A (ja) リガンドファミリーのｎｔｎ−２メンバー
CN106459993A (zh) Fgfr融合体
WO2020081556A2 (en) Non-canonical swi/snf complex and uses thereof
JP4975444B2 (ja) 創薬標的タンパク質及び標的遺伝子、並びにスクリーニング方法
JPWO2007026969A1 (ja) 創薬標的タンパク質及び標的遺伝子、並びにスクリーニング方法
US20070117138A1 (en) Splice variant cannabinoid receptor (cb1b)
JP2002523078A (ja) 新規なｉｒａｐ−ｂｐポリペプチド及び核酸分子並びにこれらの利用法
AU2003244713A1 (en) Histone deacetylase: novel molecular target of neurotoxicity
CA2332121A1 (en) Methods for inhibiting tef-3 activity
JP2002534114A (ja) 新規ｌｒｓｇタンパク質および核酸分子ならびにそのための用途
JPH09506243A (ja) レセプター認識因子、蛋白配列およびその使用方法
JP2002508934A (ja) Ｔｎｆレセプターに対して相同性を有する、新規な核酸およびポリペプチド
US20160187340A1 (en) Compositions, Kits, and Methods for the Modulation of Immune Responses Using Galectin-1
WO1997031931A1 (en) A novel disintegrin metalloprotease and methods of use
US20020102614A1 (en) Use of ZPR1 as a molecular probe for spinal muscular atrophy
JPH11501817A (ja) ヒト臍静脈内皮細胞で発現されるヒアルロン酸レセプタ
JPH10337192A (ja) ヒトプロテインキナーゼｈｏａｃｆ７２
JP2002509707A (ja) 肺腫瘍細胞を同定するための組成物および方法
EP1613769A1 (en) Insulin-induced gene as therapeutic target in diabetes
JP2003530883A (ja) Ｎｆ−ａｔ相互作用タンパク質ｎｉｐ４５変異体の調節
US20040033226A1 (en) Osteopontin, oligodendrocytes and myelination
JP2005535313A (ja) オステオポンチン、オリゴデンドロサイトおよび髄鞘形成
Blanco DNA polymerase mu and uses thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued